Evidence map›Paper›PMID 17728222›Full record

ArticleJournal of virology2007

Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.

Yi Liu, John McNevin, Hong Zhao, Denis M Tebit, Ryan M Troyer, Matthew McSweyn, Ananta K Ghosh, Daniel Shriner, Eric J Arts, M Juliana McElrath and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Restriction-modification systems are required forProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Restriction-modification systems are required forbioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Design and Pharmacological Characterization of a Novel Antithrombotic P2YInternational journal of molecular sciences · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. En route to Peptide Therapeutics for COVID 19: Harnessing Potential Antigenic Mimicry Between Viral and Human Proteins.Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yi LiuDepartment of Microbiology, University of Washington School of Medicine, Seattle, WA 98195-8070, USA.
John McNevin
Hong Zhao
Denis M Tebit
Ryan M Troyer
Matthew McSweyn
Ananta K Ghosh
Daniel Shriner
Eric J Arts
M Juliana McElrath
James I Mullins
Case Western Reserve University · USFred Hutch Cancer Center · USUniversity of Washington · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
ZIPRASIDONE IN NORMAL HEPATIC FUNCTION SUBJECTS &IN HEPATIC DYSFUCTIN SUBJECTSM01RR000037 · NCRR · UNIVERSITY OF WASHINGTON · PI MCDONALD, RUTH C · 1985 to 2007
$33.8M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
Occurrence and Outcome of Dual HIV-1 InfectionR37AI047734 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2005 to 2014
$5.9M
NCRR NIH HHS M01 RR000037NCRR NIH HHS M01 RR00037NIAID NIH HHS AI27757NIAID NIH HHS AI57005NIAID NIH HHS P01 AI057005NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI049170NIAID NIH HHS R37 AI047734NIAID NIH HHS R37 AI47734
6 · The paper itself

Abstract

CD8(+) cytotoxic T lymphocytes (CTL) are strong mediators of human immunodeficiency virus type 1 (HIV-1) control, yet HIV-1 frequently mutates to escape CTL recognition. In an analysis of sequences in the Los Alamos HIV-1 database, we show that emerging CTL escape mutations were more often present at lower frequencies than the amino acid(s) that they replaced. Furthermore, epitopes that underwent escape contained amino acid sites of high variability, whereas epitopes persisting at high frequencies lacked highly variable sites. We therefore infer that escape mutations are likely to be associated with weak functional constraints on the viral protein. This was supported by an extensive analysis of one subject for whom all escape mutations within defined CTL epitopes were studied and by an analysis of all reported escape mutations of defined CTL epitopes in the HIV Immunology Database. In one of these defined epitopes, escape mutations involving the substitution of amino acids with lower database frequencies occurred, and the epitope soon reverted back to the sensitive form. We further show that this escape mutation substantially diminished viral fitness in in vitro competition assays. Coincident with the reversion in vivo, we observed the fixation of a mutation 3 amino acids C terminal to the epitope, coincident with the ablation of the corresponding CTL response. The C-terminal mutation did not restore replication fitness reduced by the escape mutation in the epitope and by itself had little effect on replication fitness. Therefore, this C-terminal mutation presumably impaired the processing and presentation of the epitope. Finally, for one persistent epitope, CTL cross-reactivity to a mutant form may have suppressed the mutant to undetected levels, whereas for two other persistent epitopes, each of two mutants showed poor cross-reactivity and appeared in the subject at later time points. Thus, a viral dynamic exists between the advantage of immune escape, peptide cross-reactivity, and the disadvantage of lost replication fitness, with the balance playing an important role in determining whether a CTL epitope will persist or decline during infection.

Indexed as

Evolution, MolecularAmino Acid SequenceAntigenic VariationEpitopes, T-LymphocyteHIV-1HumansMolecular Sequence DataMutationT-Lymphocytes, CytotoxicEpitopes, T-Lymphocyte

Identifiers

PMID17728222
PMCPMC2169017
OpenAlexW2098739109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.